Cost Effectiveness of Tobramycin Versus Azithromycin as First-Line Therapy for Acute Exacerbations Among Patients with Non-Cystic Fibrosis Bronchiectasis

May 1, 2018, 00:00
10.1016/j.jval.2018.04.1594
https://www.valueinhealthjournal.com/article/S1098-3015(18)31900-4/fulltext
Title : Cost Effectiveness of Tobramycin Versus Azithromycin as First-Line Therapy for Acute Exacerbations Among Patients with Non-Cystic Fibrosis Bronchiectasis
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(18)31900-4&doi=10.1016/j.jval.2018.04.1594
First page :
Section Title :
Open access? : No
Section Order : 823
Categories :
Tags :
Regions :
ViH Article Tags :